Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70-75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Mar 1 2016|
Bibliographical notePublisher Copyright:
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
- acute promyelocytic leukemia
- bone marrow transplant
- umbilical cord blood